C - Chemistry – Metallurgy – 07 – C
Patent
C - Chemistry, Metallurgy
07
C
C07C 255/59 (2006.01)
Patent
CA 2543882
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson~s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, including alcohol and nicotine addiction, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.
L'invention concerne de nouveaux composés de formule structurale (I), qui sont des antagonistes et/ou agonistes inverses du récepteur cannabinoïde-1 (CB-1), et qui peuvent être utilisés pour traiter, prévenir et supprimer des maladies dont la médiation est assurée par le récepteur CB1. Les composés selon l'invention peuvent être employés en tant que médicaments à action centrale pour traiter psychoses, déficiences de la mémoire, troubles cognitifs, migraine, neuropathie, troubles neuro-inflammatoires parmi lesquels figurent sclérose en plaques et syndrome de Guillain-Barré, et des séquelles inflammatoires d'une encéphalite virale, accidents vasculaires cérébraux, et des traumatismes crâniens, troubles anxieux, stress, épilepsie, maladie de Parkinson, troubles du mouvement, et schizophrénie. Les composés selon l'invention peuvent en outre servir à traiter des troubles de consommation abusive de substances, parmi lesquels figurent l'alcoolisme et le nicotinisme, l'obésité et des troubles alimentaires, l'asthme, la constipation, la pseudo-obstruction intestinale chronique, et la cirrhose hépatique.
Hagmann William K.
Qi Hongbo
Shah Shrenik K.
Truong Quang T.
Merck & Co. Inc.
Merck Sharp & Dohme Corp.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Aralkyl amines as cannabinoid receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aralkyl amines as cannabinoid receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aralkyl amines as cannabinoid receptor modulators will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1843607